Share
Save
Silexan in the Treatment Of Posttraumatic Stress Disorder Trial
Posttraumatic stress disorder (PTSD) is a common and debilitating mental illness. Current treatments for PTSD include psychotherapy and antidepressant medications. Many patients are unable to tolerate psychotherapy for PTSD and drop out of it.
In addition, its effectiveness is limited. Up to 50 percent of patients who receive psychotherapy do not benefit from it. Antidepressant medications have only small benefits in PTSD.
They also have unpleasant side effects that can make patients unwilling to take them. There is an urgent need to develop new treatments for PTSD that work and are well-tolerated. Silexan has the potential to provide an important alternative treatment for PTSD.
Silexan is derived from lavender oil. It is taken orally in the form of capsules. It is currently available over-the-counter in 14 countries, including Australia and the United States.
Previous research has shown that it is an effective treatment for anxiety disorders, including Generalized Anxiety Disorder. It is also well-tolerated by patients. The only side effects that have been identified so far are mild gastrointestinal symptoms (including burping and breath odour) and these are uncommon.
The results of a small pilot study suggest that Silexan may also be effective and well-tolerated in PTSD. The STOP trial is a clinical trial that aims to investigate whether adding Silexan to treatment-as-usual improves PTSD symptoms in adults with PTSD. The trial will recruit 224 participants.
Participants will be randomly assigned to take Silexan or a placebo (look-alike dummy pills) daily in addition to their usual medications for 12 weeks. The severity of their PTSD symptoms will be assessed prior to and at the end of this 12-week period. The STOP trial has the potential to obtain definitive evidence regarding whether Silexan helps treat symptoms of PTSD.
If Silexan is found to be an effective treatment for PTSD, the pool of patients who could potentially benefit from this treatment includes any adults with PTSD. Silexan is already available over-the-counter at a relatively low cost so there will be few barriers to accessing this treatment.
Study details:
Background: Posttraumatic stress disorder (PTSD) is a common and debilitating psychiatric disorder. Existing PTSD treatments have very significant limitations. Current evidence-based treatments for PTSD include trauma-focussed psychotherapy and antidepressant medications, including selective serotonin reuptake inhibitors and the serotonin noradrenaline reuptake inhibitor venlafaxine.
Many patients are unable to tolerate trauma-focussed psychotherapy. Uptake is relatively low and dropout rates are high. In addition, up to 50% of patients fail to respond to this therapy.
Antidepressant medications have small clinical effects and are associated with unpleasant side effects that can lead to non-adherence. There is an urgent need for new treatments for PTSD that are effective and well-tolerated. Silexan has the potential to provide a transformative alternative to these treatments.
It is an orally administered lavender oil preparation whose main constituents are the monoterpenoids linalool and linalyl acetate. It is available over-the-counter in 14 countries, including Australia and the United States. It has a novel pharmacodynamic profile that includes potent inhibition of voltage-gated calcium channels and reduction of serotonin 1A receptor binding potential.
Silexan is an effective treatment for Generalized Anxiety Disorder (GAD) and other anxiety disorders. A 2019 independent meta-analysis of data from five randomized controlled trials involving 1,320 participants with anxiety disorders found that Silexan 160 mg out-performed paroxetine and lorazepam in reducing anxiety symptoms. Silexan is also well-tolerated.
The only adverse effects that have been identified so far are mild gastrointestinal symptoms and these are uncommon. Promising pilot data suggest that Silexan may also be effective and well-tolerated in PTSD. Hypothesis: The primary hypothesis is that Silexan, as an adjunct to treatment-as-usual, over 12 weeks will be superior to placebo in improving PTSD symptoms in adults with PTSD.
Specific aims: The trial aims to investigate the effectiveness of adjunctive Silexan, compared with placebo, over 12 weeks in improving PTSD symptoms. The primary outcome measure will be the between-group change from baseline in the total symptom severity score on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Study design: The trial is a phase 3, 12-week, multi-site, parallel-arm, randomized, placebo-controlled, double-blind trial.
Participants will be adults with PTSD without comorbid psychosis, bipolar disorder, moderate or severe substance use disorder or Borderline Personality Disorder. Participants randomized to the Silexan arm will receive Silexan 160 mg daily for 12 weeks in addition to their usual prescribed medications. Participants randomized to the placebo arm will receive capsules containing an inert placebo.
The target sample size will be 156 participants, or 78 per arm. The study will recruit 224 participants to account for a 30% drop-out rate. Clinical impact: There is an urgent need to develop new treatments for PTSD that are effective and well-tolerated.
This trial has the potential to provide definitive evidence of the efficacy of Silexan in adult PTSD. Silexan is safe, well-tolerated, currently available and affordable, facilitating a rapid translation into clinical care. If Silexan is found to be an effective treatment for PTSD, the pool of patients who could potentially benefit from this treatment includes any adults with PTSD.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 18 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2024-08-26
Primary completion: 2027-02-28
Study completion finish: 2027-03-31
Study type
TREATMENT
Phase
PHASE3
Trial ID
NCT06412757
Intervention or treatment
DRUG: Silexan
OTHER: Placebo
Conditions
- • Post Traumatic Stress Disorder
Find a site
Closest Location:
Austin Health
Research sites nearby
Select from list below to view details:
Austin Health
Heidelberg, Victoria, Australia
University of Melbourne
Carlton, Victoria, Australia
Deakin University
Geelong, Victoria, Australia
Ramsay Clinic Albert Road
Melbourne, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Silexan 160 mg
| DRUG: Silexan
|
PLACEBO_COMPARATOR: Placebo
| OTHER: Placebo
|
What is the study measuring?
Primary outcome
| Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
|---|---|---|
| Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | The Primary Outcome Measure will be the between-group difference in the change from baseline to week 12 in the total symptom severity score on the CAPS-5. The CAPS-5 has good internal consistency, inter-rater reliability, test-retest reliability and convergent validity in measuring PTSD symptom severity, and is regarded as the gold-standard for measuring PTSD symptoms in research settings. The CAPS-5 will be used to query the presence of PTSD symptoms across the two weeks prior to each CAPS-5 assessment. We will also compare between-group differences in remission rates of PTSD, as determined by the CAPS-5. | At baseline and at week 12 of the study period |
Secondary outcome
| Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
|---|---|---|
| Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 16 (while including all available time-points including the off-treatment period) in the total symptom severity score on the CAPS-5. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The CAPS-5 has good internal consistency, inter-rater reliability, test-retest reliability and convergent validity in measuring PTSD symptom severity, and is regarded as the gold-standard for measuring PTSD symptoms in research settings. The CAPS-5 will be used to query the presence of PTSD symptoms across the two weeks prior to each CAPS-5 assessment. | At baseline, at week 12 and at week 16 of the study period |
| Hamilton Anxiety Rating Scale (HAM-A) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of anxiety symptoms on the HAM-A. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Hamilton Anxiety Rating Scale consists of 14 items and is the most widely used interview instrument for measurement of anxiety in adults and children. | At baseline, at week 12 and at week 16 of the study period |
| Generalized Anxiety Disorder-7 (GAD-7) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of anxiety symptoms on the GAD-7. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Generalized Anxiety Disorder-7 is a 7-item scale with each item scores on a scale of 0 ("not at all") to 3 ("nearly every day") based on symptom presentation in the past two weeks. | At baseline, at week 12 and at week 16 of the study period |
| Generalized Anxiety Disorder-7 (GAD-7) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of anxiety symptoms on the GAD-7, measured at baseline, week 4, week 8 and week 12 of treatment. The Generalized Anxiety Disorder-7 is a 7-item scale with each item scores on a scale of 0 ("not at all") to 3 ("nearly every day") based on symptom presentation in the past two weeks. | At baseline, week 4, week 8 and week 12 of the study period |
| Beck Depression Inventory-II (BDI-II) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of depressive symptoms on the BDI-II. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The BDI-II comprises of 21 questions rated on 4-point scales of severity (0-3), with a total score that reflects the level or degree of depression. The BDI-II has high internal consistency. | At baseline, at week 12 and at week 16 of the study period |
| Patient Health Questionnaire-9 (PHQ-9) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of depressive symptoms on the PHQ-9. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Patient Health Questionnaire-9 is a screening measure of depressive symptoms. The PHQ-9 asks participants to rate each of the 9 DSM-IV criteria for major depressive disorder from 0 ("not at all") to 3 ("nearly every day"). | At baseline, at week 12 and at week 16 of the study period |
| Patient Health Questionnaire-9 (PHQ-9) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of depressive symptoms on the PHQ-9, measured at baseline, week 4, week 8 and week 12 of treatment. The Patient Health Questionnaire-9 is a screening measure of depressive symptoms. The PHQ-9 asks participants to rate each of the 9 DSM-IV criteria for major depressive disorder from 0 ("not at all") to 3 ("nearly every day"). | At baseline, week 4, week 8 and week 12 of the study period |
| Patient Health Questionnaire-15 (PHQ-15) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of somatic symptoms on the PHQ-15. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Patient Health Questionnaire-15 is a Patient Health Questionnaire module designed to assess the presence of somatic symptoms. The PHQ-15 has good internal consistency and test-retest reliability. | At baseline, at week 12 and at week 16 of the study period |
| Patient Health Questionnaire-15 (PHQ-15) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of somatic symptoms on the PHQ-15, measured at baseline, week 4, week 8 and week 12 of treatment. The Patient Health Questionnaire-15 is a Patient Health Questionnaire module designed to assess the presence of somatic symptoms. The PHQ-15 has good internal consistency and test-retest reliability. | At baseline, week 4, week 8 and week 12 of the study period |
| Pittsburgh Sleep Quality Index, with Addendum for PTSD (PSQI & PSQI-A) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of sleep quality on the PSQI \& PSQI-A. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Pittsburgh Sleep Quality Index is designed to measure overall sleep quality during the previous month in a clinical population. The PSQI comprises 19 questions across 7 domains or "component" scores, each weighted equally on a 0-3 scale. The PSQI will include the PTSD Addendum (PSQI-A), which are 10 additional questions designed to assess the frequency of disruptive nocturnal behaviours. | At baseline, at week 12 and at week 16 of the study period |
| Pittsburgh Sleep Quality Index, with Addendum for PTSD (PSQI & PSQI-A) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of sleep quality on the PSQI \& PSQI-A, measured at baseline, week 4, week 8 and week 12 of treatment. The Pittsburgh Sleep Quality Index is designed to measure overall sleep quality during the previous month in a clinical population. The PSQI comprises 19 questions across 7 domains or "component" scores, each weighted equally on a 0-3 scale. The PSQI will include the PTSD Addendum (PSQI-A), which are 10 additional questions designed to assess the frequency of disruptive nocturnal behaviours. | At baseline, week 4, week 8 and week 12 of the study period |
| Alcohol Use Disorders Identification Test (AUDIT) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of problematic alcohol use on the AUDIT. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Alcohol Use Disorders Identification Test is a 10-item questionnaire developed through a 6-country World Health Organization collaborative project, as a screening tool for harmful alcohol consumption. The AUDIT spans the domains of alcohol consumption, drinking behaviour, and alcohol-related problems that may have occurred in the past year, as well as lifetime exposure. | At baseline, at week 12 and at week 16 of the study period |
| Alcohol Use Disorders Identification Test (AUDIT) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of problematic alcohol use on the AUDIT, measured at baseline, week 4, week 8 and week 12 of treatment. The Alcohol Use Disorders Identification Test is a 10-item questionnaire developed through a 6-country World Health Organization collaborative project, as a screening tool for harmful alcohol consumption. The AUDIT spans the domains of alcohol consumption, drinking behaviour, and alcohol-related problems that may have occurred in the past year, as well as lifetime exposure. | At baseline, week 4, week 8 and week 12 of the study period |
| World Health Organization (WHO) Disability Assessment Schedule (WHODAS 2.0) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of functional disability on the WHODAS 2.0. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The 12-item self-report version of the World Health Organization (WHO) Disability Assessment Schedule is a measure of functioning and disability across six major life domains due to health conditions. The WHODAS has high internal consistency and test-retest reliability. | At baseline, at week 12 and at week 16 of the study period |
| General Well Being Schedule (GWBS) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of general well-being on the GWBS. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The General Well Being Schedule is an 18-item measure of subjective psychological well-being and distress. The GWBS has good test-retest reliability, as well as internal consistency for both sexes. | At baseline, at week 12 and at week 16 of the study period |
| Assessment of Quality of Life-6D (AQoL-6D) | One of the Secondary Outcome Measures will be the between-group difference in the change from baseline to week 12, and baseline to week 16 (while including all available time-points including the off-treatment period) in measures of quality of life on the AQoL-6D. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The Assessment of Quality of Life-6D scale is a 20-item, 6-dimensional measure with each item containing between 4 and 6 response levels. The AQoL-6D assesses the following 6 domains of quality of life: Independent Living, Relationships, Mental Health, Coping, Pain and Senses. | At baseline, at week 12 and at week 16 of the study period |
| PTSD Checklist for DSM-5 (PCL-5) | One of the Secondary Outcome Measures will be the will be the between-group difference in the change from intake to week 12, and intake to week 16 (while including all available time-points including the off-treatment period) in measures of quality of life on the PCL-5. Additional comparisons for between-group differences from week 12 to week 16 will also be performed. The PTSD Checklist for DSM-5 is a 20-item self-report measure that assesses the presence and intensity of each of the 20 DSM-5 PTSD symptoms. The PCL-5 has been shown to have strong reliability and validity. A score of ≥ 33 suggests PTSD. | At intake, at week 12 and at week 16 of the study period |
| PTSD Checklist for DSM-5 (PCL-5) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of PTSD symptom severity on the PCL-5, measured at intake, and at week 2, week 4, week 6, week 8 and week 12 of treatment. The PTSD Checklist for DSM-5 is a 20-item self-report measure that assesses the presence and intensity of each of the 20 DSM-5 PTSD symptoms. The PCL-5 has been shown to have strong reliability and validity. A score of ≥ 33 suggests PTSD. | At intake, week 2, week 4, week 6, week 8 and week 12 of the study period |
| Patient Global Impression of Change Scale (PGIC) | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of patient global impression of change on the PGIC, measured at week 2, week 4, week 6, week 8 and week 12 of treatment. The Patient Global Impression of Change Scale asks participants to rate the change (if any) that they have experienced since starting treatment, on a scale of 1 ("No change") to 7 ("A great deal better and a considerable improvement that has made all the difference"). | Week 2, week 4, week 6, week 8 and week 12 of the study period |
| Actigraphy watches | One of the Secondary Outcome Measures will be the longitudinal trajectory analysis of sleep, actigraphy, and physiological measures (including mean heart rate, mean heart rate variability, mean blood pressure), measured continuously throughout the study period (baseline to week 16). | Continously from baseline until week 16 of the study period |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!